Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany

BACKGROUND: Multiple sclerosis (MS), a progressive neurodegenerative disease, greatly impacts the quality of life and economic status of people affected by this disease. In Germany, the total annual cost of MS is estimated at €40,000 per person with MS. Natalizumab has shown to slow MS disease progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Crystal, Prosser, Christine, Braun, Sebastian, Landsman-Blumberg, Pamela B, Gleissner, Erika, Naoshy, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293187/
https://www.ncbi.nlm.nih.gov/pubmed/28203098
http://dx.doi.org/10.2147/CEOR.S117962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293187/
https://www.ncbi.nlm.nih.gov/pubmed/28203098
http://dx.doi.org/10.2147/CEOR.S117962

Ejemplares similares